Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10177256 | 0.85 | NT5E (0.42) | PTGS2PTGS1RXRANR1H2NR1H3 | |
| SCHEMBL10176667 | 0.74 | PTGS2 (0.37) | PTGS2PTGS1 | |
| SCHEMBL25792027 | 0.71 | PTGS2 (0.37) | PTGS2PTGS1RXRANR1H2NR1H3 | |
| SCHEMBL30320360 | 0.71 | PTGS2 (0.37) | PTGS2PTGS1RXRANR1H2NR1H3 | |
| SCHEMBL25343216 | 0.69 | USP1 (0.39) | PTGS2HSD11B1 | |
| SCHEMBL30615104 | 0.69 | USP1 (0.39) | PTGS2HSD11B1 | |
| SCHEMBL25252227 | 0.69 | PTGS2 (0.36) | PTGS2PTGS1RXRANR1H2NR1H3 | |
| SCHEMBL10176917 | 0.68 | DGAT1 (0.35) | PTGS2PTGS1 | |
| SCHEMBL10176646 | 0.68 | DGAT1 (0.63) | — | |
| SCHEMBL10177480 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012081736-A1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-21 | — | — | WO | disclosed |